ADBE vs DHR: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Adobe Inc. · Technology
$195.16
+45.0% upside to fair value
Grade B
High Quality
VS
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(11.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
DHR |
| Current Price |
$195.16 |
$177.17 |
| Fair Value Estimate |
$282.98 |
$192.90 |
| Upside to Fair Value |
+45.0%
|
+8.9%
|
| Market Cap |
$77.6B |
$125.4B |
| Forward P/E |
11.2x
|
34.1x
|
| EV / EBITDA |
8.0x
|
20.8x
|
| Price / Sales |
3.1x
|
5.1x
|
| Price / FCF |
7.3x
|
23.7x
|
| Revenue Growth YoY |
+12.7%
|
+3.7%
|
| Gross Margin |
89.1%
|
60.7%
|
| Operating Margin |
36.1%
|
21.0%
|
| Return on Equity |
62.4%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
13.7%
|
4.22%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Adobe Inc. is a leading technology company specializing in software applications for digital media creation and digital document workflows. The business quality is high, supported by durable competitive moats including workflow entrenchment, format standards, and subscription switching costs. Adobe's strong financials include a trailing P/E of 11.15, a forward P/E of 11.15, and a P/FCF of 7.3, in…
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Accumulation Zones
| Metric |
ADBE |
DHR |
| Zone Low |
$212.24 |
$144.68 |
| Zone High |
$240.53 |
$163.97 |
| In Buy Zone? |
Yes
|
No
|